Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908852 · ClinicalTrials.gov registry record
Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT04908852 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT04908852 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This research study is being conducted to help understand how the symptoms during treatment for acute myeloid leukemia (AML) may be affected by metabolism and how best to study this association. Symptoms include experiences like fatigue, sleep disturbance, pain, and depression.
Interventions
- OTHER Blood Sample Collection - Observational Study
- OTHER Symptom questionnaires - Observational Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2023-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908852
The ClinicalTrials.gov registry entry for NCT04908852 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood Sample Collection - Observational Study is the first listed.
NCT04908852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908852 about?
NCT04908852 is a clinical study titled "Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML". This research study is being conducted to help understand how the symptoms during treatment for acute myeloid leukemia (AML) may be affected by metabolism and how best to study this association. Symptoms include experiences like fatigue, sleep disturbance, pain, and depression.
What is the current status of trial NCT04908852?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2021-07-26. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04908852?
The interventions under investigation include: Blood Sample Collection - Observational Study (OTHER), Symptom questionnaires - Observational Study (OTHER).
Who is sponsoring clinical trial NCT04908852?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.